CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has announced the successful closing of a $10 million public offering. The offering involved the sale of 1,111,200 shares of common stock at a price of $9.00 per share. The company plans to utilize the net proceeds from this offering to further the development of its product, Multikine, as well as for general corporate purposes and working capital. ThinkEquity served as the sole placement agent for the offering. The securities were offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250829759392) on August 29, 2025, and is solely responsible for the information contained therein.